Devyser launches Genomic Blood Typing assay: All blood groups, one simple test
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
Read More
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Read More